Company intelligence / Profile preview

SynPhar Laboratories

Edmonton, Alberta, Canadascholargps.com ↗

Ownership: Private
Development stage: Commercial

Overview

SynPhar Laboratories was a Canadian pharma/biotech joint venture specializing in small molecule drug discovery, notably for beta-lactamase inhibitors and anti-inflammatory agents; its key achievement was developing tazobactam, later commercialized globally within combinations such as piperacillin/tazobactam, and laying groundwork for additional antibiotics, with assets transitioned to NAEJA Pharmaceutical in 1999[3][4][5][6].

Therapeutic areas: ImmunologyNeurologyInfectious DiseasesOncologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

tazobactam

Commercial

Indications: Bacterial infections

Partnerships

Taiho Pharmaceutical (joint venture partner)[3][5][8]

Beyond the preview

Go deeper on SynPhar Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SynPhar Laboratories.

Explore the full profile